湖南中医药大学学报2024，Vol.44Issue(7)：1226-1230,5.DOI:10.3969/j.issn.1674-070X.2024.07.011
瑞戈非尼联合健脾消癌方对结直肠癌的临床疗效及免疫功能的影响
Clinical efficacy and impact on immune function of regorafenib combined with Jianpi Xiaoai Formula in treating colorectal cancer
摘要
Abstract
Objective To study the clinical efficacy and impact on immune function of regorafenib combined with Jianpi Xiaoai Formula(JPXAF)in treating colorectal cancer.Methods A total of 70 patients with colorectal cancer admitted to Oncology Department of Nanjing Hospital of Nanjing University of Chinese Medicine(The Second Hospital of Nanjing)from February 2022 to December 2023 were divided into two groups according to the random number table method.The observation group(n=35)was treated with regorafenib combined with JPXAF,while the control group(n=35)were administered with only regorafenib.Both groups were treated for 28 days.The total effective rate was evaluated.Before and after treatment,T lymphocyte(CD3+),helper T cells(CD4+),CD4+/cytotoxic T cells(CD8+),carbohydrate antigens(CA125,CA19-9,CA242),carcinoembryonic antigen(CEA),interleukin-6(IL-6),interleukin-10(IL-10),and tumor necrosis factor-α(TNF-α)were measured.The adverse reactions(such as nausea and vomiting,skin reaction of hands and feet,diarrhea,abnormal function of liver and kidney)were recorded.Results The total effective rate of the observation group was 57.14%,which was higher than the 42.86%in the control group(P<0.05).After treatment,the levels of serum CD3+,CD4+,CD4+/CD8+in both groups were significantly higher than those before treatment(P<0.05),and the levels of CD3+,CD4+,and CD4+/CD8+in the observation group were all higher than those in the control group(P<0.05).After treatment,the levels of CA125,CA19-9,CA242,and CEA in both groups were lower than those before treatment(P<0.05),and the levels of CA125,CA19-9,CA242,and CEA in the observation group were all lower than those in the control group(P<0.05).Post-treatment,the levels of serum IL-6,IL-10,and TNF-α were lower in both groups than before treatment(P<0.05),and the levels of IL-6,IL-10,and TNF-α in the observation group were all lower than those in the control group(P<0.05).During the treatment,there was no statistically significant difference in the total incidence of adverse reactions between the two groups(P＞0.05).Conclusion Regorafenib combined with JPXAF has a good therapeutic effect on colorectal cancer,which can reduce inflammatory response,regulate immune function,and lower tumor marker levels,with few adverse reactions.Therefore,it is worthy of clinical promotion.关键词
结直肠癌/健脾消癌方/瑞戈非尼/炎性反应/免疫功能/肿瘤标志物Key words
colorectal cancer/Jianpi Xiaoai Formula/regorafenib/inflammatory response/immune function/tumor marker分类
医药卫生引用本文复制引用
宋琳,胡灿红,蒋益兰,王清波..瑞戈非尼联合健脾消癌方对结直肠癌的临床疗效及免疫功能的影响[J].湖南中医药大学学报,2024,44(7):1226-1230,5.基金项目
国家自然科学基金面上项目(81373602) （81373602）
南京市第二医院人才托举工程资助项目(RCZD23005). （RCZD23005）
